Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
July 19, 2023 08:00 ET
|
Tempest Therapeutics
In vitro and in vivo data show significant increased potency by blocking prostaglandin PGE2 signaling through both EP2 and EP4 receptors compared to celecoxib or single EP4 antagonists TPST-1495...
Tempest to Present at the Jefferies Global Healthcare Conference
May 31, 2023 16:05 ET
|
Tempest Therapeutics
BRISBANE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
May 25, 2023 17:00 ET
|
Tempest Therapeutics
• Data show tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab • Oral, once-daily cancer treatment well tolerated with a manageable safety...
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 19, 2023 16:05 ET
|
Tempest Therapeutics
BRISBANE, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023 16:15 ET
|
Tempest Therapeutics
BRISBANE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and...
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
April 28, 2023 08:00 ET
|
Tempest Therapeutics
Positive randomized data with TPST-1120 combined with atezolizumab + bevacizumab compared head-to-head with atezolizumab + bevacizumabThe addition of TPST-1120 resulted in a clinically-meaningful...
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
April 27, 2023 16:58 ET
|
Tempest Therapeutics
BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
April 26, 2023 18:41 ET
|
Tempest Therapeutics
BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
April 17, 2023 09:00 ET
|
Tempest Therapeutics
BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
Tempest Reports Year End 2022 Financial Results and Provides Business Update
March 22, 2023 17:26 ET
|
Tempest Therapeutics
Positive monotherapy and combination therapy data from Phase 1 trial of first clinical program, TPST-1120, announced in an oral presentation at ASCO 2022 TPST-1120 randomized combination study in...